OSCR just reported the quarter, and the numbers tell two different stories depending on where you look.
Q1 2026 EPS came in at $2.07, more than double the $1.01 consensus estimate. Revenue of $4.65 billion was a 53% year-over-year leap, powered by 3.2 million members — membership up 56% from a year ago. The medical loss ratio fell nearly 490 basis points to 70.5%. Yet the stock fell 3.4% on the day to $17.94, and full-year revenue guidance was reaffirmed in line with the existing Street estimate rather than raised. Management's cautious framing on ACA market contraction — tracking toward a 20%–30% enrollment decline — seems to have tempered the earnings beat.
Options positioning captured that wariness in advance. The put/call ratio climbed to 0.43 by Tuesday, more than two standard deviations above its 20-day mean of 0.39 — the most defensively skewed reading in several weeks. That suggested traders were hedging going into the print, not chasing upside. The signal proved directionally correct: the stock softened even as the earnings beat was substantial. Cost to borrow remains negligible at 0.43%, down roughly 18% from the prior week. Availability in the lending market is ample, keeping squeeze risk low. Short interest of 11.3% of free float is meaningful but has been moving in the right direction — down 11% over the past month as shorts trimmed positions while the stock rallied more than 50% in April.
The Street has been steadily turning less negative, and Q1 reinforces why. Jefferies upgraded to Hold from Underperform on April 20, lifting its target from $10 to $16. Wolfe Research initiated coverage at Peer Perform on May 6, the earnings day itself — a notably cautious entry point after a 50% one-month rally. The current mean price target of $17.10 is essentially in line with the close, meaning the consensus sees near-zero further upside from here even after upgrades. The bull case centres on Oscar's MLR improvement, rising per-member premiums, and its technology platform's ability to drive cost efficiencies. Bears point to the risk that ACA subsidy expiration strips out 6+ million lower-acuity members, leaving a sicker, more expensive risk pool and undermining the profitability progress shown in Q1.
Factor scores reinforce the earnings story. EPS momentum ranks in the 99th percentile over 90 days and the 100th percentile over 30 days — the company has been beating estimates consistently. The analyst recommendation divergence score ranks in the 94th percentile, reflecting how much recent upgrades have diverged from a previously more bearish consensus. The short score of 49.6 is firmly mid-range, consistent with a stock where short sellers are present but not pressing.
One piece of insider context is worth flagging. CEO Mark Bertolini bought $11.9 million worth of stock on April 6 — right at the trough of the market-wide selloff when shares were around $11.92. That same day he filed an offsetting sell of equal size, which looks like a same-day exercise-and-sell, with the net economic result being the large restricted stock award of 5.7 million shares granted on April 3 forming the real commitment. Taken together, Bertolini increased his reported position to 8.6 million shares by early April — a 6.7 million share addition to the register. That's a material alignment of interest heading into a print where he told investors Oscar is "well positioned to meet or exceed" current guidance.
With Q1 now in the books and guidance reaffirmed, the next focal point is how ACA market contraction data develops through Q2 — management flagged the first Wakely report in the second quarter as the next meaningful read on 2026 morbidity trends, and Investor Day is pencilled for September 16.
See the live data behind this article on ORTEX.
Open OSCR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
